Pelthos Therapeutics Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment

Reuters

2025/09/04

Pelthos <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment

Pelthos Therapeutics Inc. has released its latest investor presentation, highlighting key aspects of its corporate profile and recent developments. The company, trading under the ticker PTHS, has a stock price of $23.65 and a market capitalization of approximately $205 million. Pelthos recently launched Zelsuvmi, a treatment for Molluscum contagiosum, marking the first at-home treatment option for this contagious viral disease. The addressable market for this treatment is valued at over $20 billion, with up to 6 million annual cases in the U.S. Pelthos aims for a peak net revenue forecast of $175 million per annum by 2028. The management team, led by CEO Scott Plesha, has extensive experience in successful drug launches. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief on September 02, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2564300314"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564300314\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564300314?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 04:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564300314","market":"fut","top_or_hot":-1,"title":"Pelthos Therapeutics Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pelthos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pelthos Therapeutics Inc. has released its latest investor presentation, highlighting key aspects of its corporate profile and recent developments. The company, trading under the ticker PTHS, has a stock price of $23.65 and a market capitalization of approximately $205 million. Pelthos recently launched Zelsuvmi, a treatment for Molluscum contagiosum, marking the first at-home treatment option for this contagious viral disease. The addressable market for this treatment is valued at over $20 billion, with up to 6 million annual cases in the U.S. Pelthos aims for a peak net revenue forecast of $175 million per annum by 2028. The management team, led by CEO Scott Plesha, has extensive experience in successful drug launches. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pelthos Therapeutics Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPelthos Therapeutics Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-04 04:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pelthos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pelthos Therapeutics Inc. has released its latest investor presentation, highlighting key aspects of its corporate profile and recent developments. The company, trading under the ticker PTHS, has a stock price of $23.65 and a market capitalization of approximately $205 million. Pelthos recently launched Zelsuvmi, a treatment for Molluscum contagiosum, marking the first at-home treatment option for this contagious viral disease. The addressable market for this treatment is valued at over $20 billion, with up to 6 million annual cases in the U.S. Pelthos aims for a peak net revenue forecast of $175 million per annum by 2028. The management team, led by CEO Scott Plesha, has extensive experience in successful drug launches. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL7K5rvN:1","article_id":"2564300314","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564300314","pubTimestamp":1756932625,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pelthos Therapeutics Inc. has released its latest investor presentation, highlighting key aspects of its corporate profile and recent developments. The company, trading under the ticker PTHS, has a stock price of $23.65 and a market capitalization of approximately $205 million. Pelthos recently launched Zelsuvmi, a treatment for Molluscum contagiosum, marking the first at-home treatment option for this contagious viral disease. The addressable market for this treatment is valued at over $20 billion, with up to 6 million annual cases in the U.S. Pelthos aims for a peak net revenue forecast of $175 million per annum by 2028. The management team, led by CEO Scott Plesha, has extensive experience in successful drug launches. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","PTHS":"PELTHOS THERAPEUTICS INC"},"translate_title":"Pelthos Therapeutics Inc.发布投资者演示文稿，重点介绍用于传染性软疣治疗的Zelsuvmi的推出","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTHS":0.9},"content_text":"Pelthos Therapeutics Inc. Unveils Investor Presentation Highlighting Launch of Zelsuvmi for Molluscum Contagiosum Treatment\n    \n\n        Pelthos Therapeutics Inc. has released its latest investor presentation, highlighting key aspects of its corporate profile and recent developments. The company, trading under the ticker PTHS, has a stock price of $23.65 and a market capitalization of approximately $205 million. Pelthos recently launched Zelsuvmi, a treatment for Molluscum contagiosum, marking the first at-home treatment option for this contagious viral disease. The addressable market for this treatment is valued at over $20 billion, with up to 6 million annual cases in the U.S. Pelthos aims for a peak net revenue forecast of $175 million per annum by 2028. The management team, led by CEO Scott Plesha, has extensive experience in successful drug launches. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief on September 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}